Home Cart Sign in  
Chemical Structure| 110623-72-8 Chemical Structure| 110623-72-8

Structure of Epimedin A
CAS No.: 110623-72-8

Chemical Structure| 110623-72-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Epimedin A is a natural compound extracted from Herba Epimedii.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Yuan, Jiaying ; Wang, Yuhan ; Sha, Bingxian ; Zhang, Yunfeng ; Mokuy, Ondo Osie Eloina Margarita ; Jin, Mingming , et al.

Abstract: Background: Chuankezhi injection (CKZ), derived from the traditional Chinese herbs Ying-Yang-Huo (Epimedium brevicornu Maxim) and Ba-Ji-Tian (Morinda officinalis F.C. How), has demonstrated remarkable clinical effects in the treatment of asthma. However, the underlying mechanisms remain unclear. Purpose: This study aims to explore the mechanisms and molecular targets of CKZ in the treatment of asthma, utilizing network pharmacology and molecular biology experiments. Study Design: A combination of network pharmacology and experimental validation was used to identify the specific targets and pathways through which CKZ exerts its effects on asthma. In vitro and in vivo experiments were conducted to further verify the findings. Methods: Liquid chromatography-mass spectrometry (LC/MS) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry were employed to identify the components of CKZ. GeneCards was used to gather asthma-related targets, and the STRING online database was utilized to construct protein-protein interaction (PPI) networks. Hub genes were identified from the PPI network and analyzed through Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. In vitro and in vivo experiments were conducted to validate the network pharmacology predictions. Results: LC/MS and MALDI-TOF analysis revealed that CKZ is rich in flavonoid compounds. Network pharmacological analysis identified , AKT1, IL-6, GAPDH, and as the top five hub genes. GO and KEGG pathway analyses suggested that CKZ’s effect on asthma is closely associated with mitochondrial function and the mitogen-activated protein kinase (MAPK) signaling pathway. In vivo and in vitro experiments showed that CKZ treatment alleviated airway inflammation and collagen deposition in asthma mouse models, as demonstrated by HE, PAS, and Masson staining. CKZ also reduced the levels of inflammatory cytokines (IL-4, IL-5, IL-13, and TNF-α) in bronchoalveolar lavage fluid (BALF) and serum. Furthermore, CKZ improved mitochondrial damage and inhibited the activation of the MAPK signaling pathway, as confirmed by Western blotting analysis. Conclusion: CKZ effectively alleviates airway inflammation and improves airway damage in asthma by inhibiting the MAPK signaling pathway. These findings suggest that CKZ is a promising therapeutic option for asthma treatment.

Keywords: Chuankezhi injection ; Traditional Chinese Medicine (TCM) ; asthma ; Network pharmacology ; molecular docking ; MAPK signaling pathway ; treatment

Purchased from AmBeed: ; ;

Alternative Products

Product Details of Epimedin A

CAS No. :110623-72-8
Formula : C39H50O20
M.W : 838.80
SMILES Code : O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](OC2=CC(O)=C(C(C(O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O[C@@]4([H])[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C(C5=CC=C(OC)C=C5)O6)=O)C6=C2C/C=C(C)/C)[C@@H]1O
MDL No. :MFCD30496681

Safety of Epimedin A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse preosteoblastic cell line MC3T3-E1 0.5, 1, 2 mg/mL 14 days To evaluate the effect of Epimedin A complex drug on proliferation and differentiation of MC3T3-E1 cells. Results showed EA significantly promoted cell proliferation, ALP activity, calcium nodule formation, and osteogenesis-related gene/protein expression. J Mater Sci Mater Med. 2021 Jan 27;32(1):17
human osteoarthritic chondrocytes 1 μM, 10 μM, 25 μM, 50 μM 2 weeks To assess the anabolic effect of Epimedin A on cartilage matrix synthesis, results showed that Epimedin A significantly increased the GAG/DNA ratio. Int J Mol Sci. 2019 Nov 15;20(22):5745
RAW264.7 cells 0.1 μM, 0.2 μM, 0.4 μM 5 days To investigate the effect of EA on RANKL-induced osteoclast differentiation, results showed that EA inhibited osteoclast differentiation in a concentration-dependent manner. Mol Med. 2024 Aug 16;30(1):125

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Cisplatin-induced intestinal injury model Gavage 100, 200 mg/kg 10 consecutive days EFE significantly attenuated cisplatin-induced intestinal damage by regulating oxidative stress, inflammation, and apoptosis Front Pharmacol. 2022 Oct 12;13:1040504
Female mice OVX-induced osteoporosis model Intragastric administration 5, 10, 20 mg/kg Once daily for 8 weeks To assess the therapeutic effect of Epimedin A on osteoporosis in OVX mice. Results demonstrated high-dose EA significantly enhanced bone strength, improved microstructure, and upregulated bone formation-related genes. J Mater Sci Mater Med. 2021 Jan 27;32(1):17
Wistar rats Ovariectomy-induced osteoporosis model Oral 5 mg/kg/d, 10 mg/kg/d, 20 mg/kg/d Once daily for 90 days To investigate the protective effect of EA on ovariectomy-induced osteoporosis, results showed that EA significantly improved bone mineral density and trabecular microstructure. Mol Med. 2024 Aug 16;30(1):125

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.19mL

0.24mL

0.12mL

5.96mL

1.19mL

0.60mL

11.92mL

2.38mL

1.19mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories